Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Rhythm Pharmaceuticals (RYTM) Leases (2018 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Leases for 8 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 12.31% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 12.31% decrease, with the full-year FY2025 number at $3.0 million, down 12.31% from a year prior.
  • Leases was $3.0 million for Q4 2025 at Rhythm Pharmaceuticals, down from $3.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.7 million in Q2 2024 to a low of $670000.0 in Q1 2024.
  • A 5-year average of $2.0 million and a median of $1.6 million in 2021 define the central range for Leases.
  • Peak YoY movement for Leases: crashed 38.42% in 2024, then surged 402.54% in 2025.
  • Rhythm Pharmaceuticals' Leases stood at $1.5 million in 2021, then fell by 22.34% to $1.2 million in 2022, then tumbled by 33.93% to $781000.0 in 2023, then soared by 345.2% to $3.5 million in 2024, then decreased by 12.31% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Leases are $3.0 million (Q4 2025), $3.2 million (Q3 2025), and $3.3 million (Q2 2025).